Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Mesotherapy for Androgenetic Alopecia: PRP, Dutasteride, Bicalutamide, Botulinum Toxin
Description
The presentation on mesotherapy for androgenetic alopecia discusses various treatment options, emphasizing that mesotherapy is generally less effective than oral medications. It highlights that while patients often prefer mesotherapy due to its perceived safety and minimal systemic side effects, it should be considered a second-line treatment. The speaker outlines four types of mesotherapy: with anti-androgens (dutasteride and bicalutamide), PRP, and botulinum toxin. Dutasteride, noted for its long half-life and enzyme-blocking properties, can improve hair density with minimal side effects, making it suitable for those averse to oral medications. Bicalutamide showed modest effects, while PRP’s effectiveness varied among patients. Botulinum toxin was described as disappointing, yielding low improvements in hair density and primarily effective for treating scalp hyperhidrosis. The speaker concludes that while oral medications and topical minoxidil remain the primary treatments, mesotherapy may serve as an adjunct for certain patients. The talk touches on the lack of standardized protocols and the need for more clinical trials in the field.
View moreConclusions
- Mesotherapy is generally less effective than oral therapies for androgenetic alopecia (AGA).
- Mesotherapy can be considered a second-line treatment option, particularly for patients who prefer non-systemic therapies.
- Dutasteride used in mesotherapy has shown moderate effectiveness and safety with negligible systemic side effects.
- Multiple treatment sessions of mesotherapy are necessary to achieve noticeable improvements in hair density.
- Other agents used in mesotherapy, such as bicalutamide and PRP, show variable effectiveness and may require more frequent administration.
- Botulinum toxin has limited effectiveness in increasing hair density in AGA and is primarily used for other scalp conditions.
- Patients who are reluctant to take oral medications or have intolerances may prefer mesotherapy with dutasteride as an adjunct treatment.
- Clinical experience suggests positive outcomes from mesotherapy with dutasteride, particularly when combined with other treatments such as oral minoxidil.
- Additional studies are necessary to standardize protocols and enhance the efficacy of mesotherapy in treating AGA.
- Galván S, Vañó-Galván S. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013 Jun;27(6):686-93. doi: 10.1111/j.1468-3083.2012.04535.x. Epub 2012 Apr 6. PMID: 22486925
- Saceda-Corralo D, Rodrigues-Barata AR, Vañó-Galván S, Jaén-Olasolo P. Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. Int J Trichology. 2017 Jul-Sep;9(3):143-145. doi: 10.4103/ijt.ijt_73_16. PMID: 28932074 Free PMC Article
- Melo DF, Ramos PM, Antelo DAP, Machado CJ, Barcaui CB. Efficacy of botulinum toxin in male androgenetic alopecia: A triple-blind, randomized clinical trial. J Am Acad Dermatol. 2024 Jul 22:S0190-9622(24)02542-8. doi: 10.1016/j.jaad.2024.07.1464. Online ahead of print. PMID: 39047987
- Li C, Pan L, Yang L, Kong J, Zhang L. An umbrella review of the use of platelet-rich plasma in the treatment of androgenetic alopecia. J Dermatolog Treat. 2022 Feb;33(1):62-72. doi: 10.1080/09546634.2020.1749547. Epub 2020 Apr 13.
- Aditya K Gupta, Mary A Bamimore, Kelly A Foley. Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. J Cosmet Dermatol. 2023 Jan 31. doi: 10.1111/jocd.15617. Online ahead of print. PMID: 36718799